Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Trial details
- Registry ID
- NCT07228832
- Drugs studied
- Drug: Bevacizumab Injection, Drug: Ivonescimab Injection
TrialRedline tracks 5 clinical trials sponsored by Summit Therapeutics: 5 Phase 3.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal CancerNCT07228832 | Drug: Bevacizumab Injection, Drug: Ivonescimab Injection | Recruiting | 2028-05-31Estimated |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1NCT06767514 | Ivonescimab Injection, Pembrolizumab Injection | Recruiting | 2028-04Estimated |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsNCT05899608 | Ivonescimab Injection, Pembrolizumab Injection | Active not recruiting | 2028-12-31Estimated |
| Phase III Study of AK112 for NSCLC PatientsNCT06396065 | AK112 Injection | Active not recruiting | 2025-04-12Actual |
| Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent SubjectsNCT04802837 | Ridinilazole, Vancomycin | Terminated | 2021-09-17Actual |
Names as written in the registry records.
NCT07228832 · Summit Therapeutics
Before: 600 participants (planned). After: 900 participants (planned).
NCT05899608 · Summit Therapeutics
Before: Recruiting. After: Active not recruiting.
NCT06396065 · Summit Therapeutics
Before: Estimated. After: Actual.
Before: Estimated. After: Actual.
Before: 31 Dec 2025. After: 12 Apr 2025.
NCT05899608 · Summit Therapeutics
Before: 1080 participants (planned). After: 1600 participants (planned).
Before: 31 Dec 2027. After: 31 Dec 2028.